Bulletin from the Extraordinary General Meeting in 2cureX AB (publ)

July 2 | 2020
Changes to the Board of directors

At the Extraordinary General Meeting of 2cureX AB (publ) today, 2 July 2020, the general meeting resolved to increase the number of members of the Board to six members. The general meeting also resolved to dismiss Timm Jessen, co-founder of 2cureX, who decided to leave the Board for personal reasons, and to appoint Nils Brünner and Michael Lutz as new board members.

Issuance authorization

The Extraordinary General Meeting resolved to authorize the Board, with or without deviation from the shareholders' pre-emptive right, at one or more occasions and for the period until the end of the next Annual General Meeting, to increase the company's share capital through a new issue of shares, warrants, and/or convertible loan notes to the extent permitted by the Articles of Association.

The terms and conditions for warrants of series 2018/2020

The Extraordinary General Meeting resolved to extend the exercise period for the warrants of series 2018/2020 from 28 September 2020 until 31 July 2021.


The information was submitted for publication, through the agency of the contact persons set out below, at 16:00 CEST on July 2, 2020.

N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the extraordinary general meeting in 2cureX AB, and in case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

For more information about 2cureX

Ole Thastrup, Chief Executive Officer

E-mail: ot@2curex.com

Telephone: +45 22 11 53 99


Certified Adviser

Redeye AB

Telephone: +46 8 121 576 90

E-mail: certifiedadviser@redeye.se

2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D micro-tumors that are similar to the patient’s tumor and identifies the treatment that most effectively kills the patient’s tumor. Immediately after the test, the patient can be offered the selected treatment.

IndiTreat® is being clinically validated in clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical programs are conducted at major cancer hospitals in Denmark, Germany, United Kingdom and Sweden.

IndiTreat® is presently being introduced into the European market through an Early Access Program.

The aspiration is that IndiTreat® becomes a standard tool in Precision Medicine for cancer patients.

The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol “2CUREX”).